FMP

FMP

Enter

HSTO - Histogen Inc.

photo-url-https://images.financialmodelingprep.com/symbol/HSTO.png

Histogen Inc.

HSTO

NASDAQ

Inactive Equity

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

0.02 USD

0 (0%)

Historical Prices

From:

To:

page loading card

About

ceo

Ms. Susan A. Knudson

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen In...

CIK

0001383701

ISIN

US43358Y2028

CUSIP

43358Y103

Address

10655 Sorrento Valley Road

Phone

858 526 3100

Country

US

Employee

7

IPO Date

Jul 25, 2013

Financial Statement

-4M-3M-2M-1M01M2022 Q32022 Q42023 Q12023 Q22023 Q3RevenueNet Income

Earnings

-1.5-1.2-0.9-0.6-0.302022 Q42023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q3EPS Consensus

HSTO Financial Summary

CIK

0001383701

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

43358Y103

ISIN

US43358Y2028

Country

US

Price

0.02

Beta

1.12

Volume Avg.

0

Market Cap

85.44k

Shares

-

52-Week

-

DCF

5.92

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.01

P/B

-

Website

https://www.histogen.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest HSTO News

PennyStocks

Mar 20, 2023

Top Sectors to Explore for Penny Stocks to Buy

Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PennyStocks

Mar 18, 2023

Penny Stock Psychology: Developing a Winning Mindset

Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

InvestorPlace

Mar 17, 2023

Why Is Histogen (HSTO) Stock Up 37% Today?

Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.

Zacks Investment Research

Jan 10, 2023

Histogen (HSTO) Upgraded to Strong Buy: Here's What You Shou...

Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PennyStocks

Nov 10, 2022

Buying Biotech Penny Stocks? 3 Things to Look For

Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire

May 17, 2022

Histogen to Present at the H.C. Wainwright Global Investment...

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen's Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

GlobeNewsWire

Apr 28, 2022

Histogen to Report First Quarter 2022 Financial Results and ...

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.

PennyStocks

Apr 19, 2022

5 Top Biotech Penny Stocks Under $1 To Watch This Week

Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep